nivolumab
bms
['nivolumab', 'nivo']
#asco22 addition of nivolumab did increase toxicity (including more febrile neutropenia). outcomes better with higher pdl1 expression. pcr rate 15% in pdl1 negative, 42% for pdl1 low, and 61% for pdl1 high. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him